SecBot SecBot
Biotech Drug Report Generated Oct 25, 2026

BREXAFEMME

SCYX·Scynexis
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved but commercially unavailable; GSK is working on a relaunch with no confirmed date as of October 2026. Shortage tracking shows 0% pharmacy availability.
Why 4/10
BREXAFEMME is already FDA-approved (2021, 2022) with no pending regulatory decision, its defining binary catalysts are in the past. The next event is GSK's commercial relaunch, which has no confirmed date, and SCYX is now a multi-asset pipeline company with SCY-247 and SCY-770 driving future catalysts.
Actionable Insight NEUTRAL

There is no hard, dated binary catalyst for BREXAFEMME itself, it is already approved and the commercial relaunch by GSK has no confirmed timeline. SCYX investors should watch the Q3 2026 earnings call (estimated Nov 11) for any GSK relaunch updates, and the start of SCY-770 Phase 2 PoC in ADPKD (expected Q4 2026) as the company's next value-driving pipeline catalyst.

Price Chart

Loading chart...

Executive Summary

BREXAFEMME (ibrexafungerp) is an oral, first-in-class triterpenoid antifungal approved by the FDA in June 2021 for vulvovaginal candidiasis (VVC) and in November 2022 for recurrent VVC. Scynexis (SCYX) licensed global rights to GSK in May 2023 for $90M upfront plus up to $503M in milestones and tiered royalties. The drug has been commercially unavailable since a September 2023 voluntary recall over cross-contamination concerns, followed by a 19-month FDA clinical hold that was lifted in 2025. The NDA was transferred to GSK in November 2025, and as of late October 2026, BREXAFEMME remains off pharmacy shelves with no confirmed relaunch date. SCYX has since pivoted to a clinical-stage pipeline (SCY-247 antifungal, SCY-770 ADPKD drug) and is no longer single-asset dependent on BREXAFEMME.

How It Works

BREXAFEMME is an oral antifungal pill that kills Candida yeast by disrupting the fungal cell wall, the first drug in a new antifungal class (triterpenoids) approved in over 20 years. It is taken by mouth as a one-day treatment for vaginal yeast infections, unlike older azole antifungals that work differently and face growing resistance.

Trial Status

FDA-approved June 2021 for vulvovaginal candidiasis (VVC) and November 2022 for reduction in incidence of recurrent VVC. The drug is currently off the market due to a voluntary recall (September 2023) and manufacturing remediation. A Phase 3 MARIO study was placed on clinical hold for 19 months (Oct 2023-May 2025) but dosing has resumed.

The Two-Sided Case

▲ Bull Case4
BREXAFEMME is the first new antifungal class in >20 years and the only FDA-approved oral non-azole for both VVC and recurrent VVC, giving it a strong differentiation story if GSK relaunches.
The GSK license provides SCYX with up to $145.5M in annual net sales milestones plus low-to-mid single-digit royalties, representing substantial non-dilutive upside if the drug returns to market.
Analyst consensus is Strong Buy (8 analysts: 5 buy, 3 strong buy, 1 hold) with a mean price target of ~$36.33, implying ~860% upside from the ~$3.79 stock price.
SCYX has extended cash runway to mid-2029 and secured a BARDA contract worth up to ~$214M for SCY-247, providing financial stability independent of BREXAFEMME's relaunch.
▼ Bear Case5
BREXAFEMME has been off the market since September 2023 due to a contamination-related recall, and as of late October 2026 it still has 0% pharmacy availability with no confirmed GSK relaunch date, over 3 years of commercial absence.
The 19-month FDA clinical hold and manufacturing issues raise questions about production reliability and GSK's ability to resolve FDA concerns quickly.
SCYX completed a 1-for-8 reverse stock split in June 2026 to maintain Nasdaq listing, signaling distress, and issued a $37.2M private placement that diluted existing holders.
FINRA short-volume data shows a weighted short-volume ratio of ~54% in the recent period, indicating elevated bearish positioning/short selling in the stock.
SCYX is now a clinical-stage company with pipeline assets (SCY-247, SCY-770) years from potential revenue, while BREXAFEMME's commercial hiatus has eliminated its near-term revenue stream.

Upcoming Catalysts

  • GSK BREXAFEMME commercial relaunch timeline (date TBD)
  • SCYX Q3 2026 earnings call (estimated Nov 11, 2026), potential GSK relaunch updates

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Scynexis Press Release SCYX ·Originating report

Sources · 10

Hover a chip for the title
1 ir.scynexis.com2 medfinder.com3 fiercepharma.com4 gsk.com5 ir.scynexis.com6 ir.scynexis.com7 ir.scynexis.com8 ashp.org9 fda.gov10 marketbeat.com